0000946563--12-31 2024 Q3 false RETRACTABLE TECHNOLOGIES INC P10Y 0000946563 rvp:SeriesTwoConvertibleClassBPreferredStockMember us-gaap:PreferredStockMember 2024-09-30 0000946563 rvp:SeriesThreeConvertibleClassBPreferredStockMember us-gaap:PreferredStockMember 2024-09-30 0000946563 us-gaap:TreasuryStockCommonMember 2024-09-30 0000946563 us-gaap:RetainedEarningsMember 2024-09-30 0000946563 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0000946563 rvp:SeriesTwoConvertibleClassBPreferredStockMember us-gaap:PreferredStockMember 2024-06-30 0000946563 rvp:SeriesThreeConvertibleClassBPreferredStockMember us-gaap:PreferredStockMember 2024-06-30 0000946563 us-gaap:TreasuryStockCommonMember 2024-06-30 0000946563 us-gaap:RetainedEarningsMember 2024-06-30 0000946563 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000946563 2024-06-30 0000946563 rvp:SeriesTwoConvertibleClassBPreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0000946563 rvp:SeriesThreeConvertibleClassBPreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0000946563 us-gaap:TreasuryStockCommonMember 2023-12-31 0000946563 us-gaap:RetainedEarningsMember 2023-12-31 0000946563 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000946563 rvp:SeriesTwoConvertibleClassBPreferredStockMember us-gaap:PreferredStockMember 2023-09-30 0000946563 rvp:SeriesThreeConvertibleClassBPreferredStockMember us-gaap:PreferredStockMember 2023-09-30 0000946563 us-gaap:TreasuryStockCommonMember 2023-09-30 0000946563 us-gaap:RetainedEarningsMember 2023-09-30 0000946563 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0000946563 rvp:SeriesTwoConvertibleClassBPreferredStockMember us-gaap:PreferredStockMember 2023-06-30 0000946563 rvp:SeriesThreeConvertibleClassBPreferredStockMember us-gaap:PreferredStockMember 2023-06-30 0000946563 us-gaap:TreasuryStockCommonMember 2023-06-30 0000946563 us-gaap:RetainedEarningsMember 2023-06-30 0000946563 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000946563 2023-06-30 0000946563 rvp:SeriesTwoConvertibleClassBPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0000946563 rvp:SeriesThreeConvertibleClassBPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0000946563 us-gaap:TreasuryStockCommonMember 2022-12-31 0000946563 us-gaap:RetainedEarningsMember 2022-12-31 0000946563 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000946563 rvp:SyringesMember rvp:OtherInternationalExcludingNorthAndSouthAmericaMember 2024-07-01 2024-09-30 0000946563 rvp:SyringesMember rvp:NorthAndSouthAmericaExcludingUnitedStatesMember 2024-07-01 2024-09-30 0000946563 rvp:SyringesMember country:US 2024-07-01 2024-09-30 0000946563 rvp:OtherProductsMember rvp:OtherInternationalExcludingNorthAndSouthAmericaMember 2024-07-01 2024-09-30 0000946563 rvp:OtherProductsMember country:US 2024-07-01 2024-09-30 0000946563 rvp:EasyPointNeedlesMember rvp:OtherInternationalExcludingNorthAndSouthAmericaMember 2024-07-01 2024-09-30 0000946563 rvp:EasyPointNeedlesMember country:US 2024-07-01 2024-09-30 0000946563 rvp:BloodCollectionProductsMember rvp:OtherInternationalExcludingNorthAndSouthAmericaMember 2024-07-01 2024-09-30 0000946563 rvp:BloodCollectionProductsMember country:US 2024-07-01 2024-09-30 0000946563 us-gaap:LicenseMember 2024-07-01 2024-09-30 0000946563 rvp:SyringesMember 2024-07-01 2024-09-30 0000946563 rvp:OtherProductsMember 2024-07-01 2024-09-30 0000946563 rvp:OtherInternationalExcludingNorthAndSouthAmericaMember 2024-07-01 2024-09-30 0000946563 rvp:NorthAndSouthAmericaExcludingUnitedStatesMember 2024-07-01 2024-09-30 0000946563 rvp:EasyPointNeedlesMember 2024-07-01 2024-09-30 0000946563 rvp:BloodCollectionProductsMember 2024-07-01 2024-09-30 0000946563 country:US 2024-07-01 2024-09-30 0000946563 rvp:SyringesMember rvp:OtherInternationalExcludingNorthAndSouthAmericaMember 2024-01-01 2024-09-30 0000946563 rvp:SyringesMember rvp:NorthAndSouthAmericaExcludingUnitedStatesMember 2024-01-01 2024-09-30 0000946563 rvp:SyringesMember country:US 2024-01-01 2024-09-30 0000946563 rvp:OtherProductsMember rvp:OtherInternationalExcludingNorthAndSouthAmericaMember 2024-01-01 2024-09-30 0000946563 rvp:OtherProductsMember rvp:NorthAndSouthAmericaExcludingUnitedStatesMember 2024-01-01 2024-09-30 0000946563 rvp:OtherProductsMember country:US 2024-01-01 2024-09-30 0000946563 rvp:EasyPointNeedlesMember rvp:OtherInternationalExcludingNorthAndSouthAmericaMember 2024-01-01 2024-09-30 0000946563 rvp:EasyPointNeedlesMember rvp:NorthAndSouthAmericaExcludingUnitedStatesMember 2024-01-01 2024-09-30 0000946563 rvp:EasyPointNeedlesMember country:US 2024-01-01 2024-09-30 0000946563 rvp:BloodCollectionProductsMember rvp:OtherInternationalExcludingNorthAndSouthAmericaMember 2024-01-01 2024-09-30 0000946563 rvp:BloodCollectionProductsMember rvp:NorthAndSouthAmericaExcludingUnitedStatesMember 2024-01-01 2024-09-30 0000946563 rvp:BloodCollectionProductsMember country:US 2024-01-01 2024-09-30 0000946563 us-gaap:LicenseMember 2024-01-01 2024-09-30 0000946563 rvp:SyringesMember 2024-01-01 2024-09-30 0000946563 rvp:OtherProductsMember 2024-01-01 2024-09-30 0000946563 rvp:OtherInternationalExcludingNorthAndSouthAmericaMember 2024-01-01 2024-09-30 0000946563 rvp:NorthAndSouthAmericaExcludingUnitedStatesMember 2024-01-01 2024-09-30 0000946563 rvp:EasyPointNeedlesMember 2024-01-01 2024-09-30 0000946563 rvp:BloodCollectionProductsMember 2024-01-01 2024-09-30 0000946563 country:US 2024-01-01 2024-09-30 0000946563 rvp:SyringesMember rvp:OtherInternationalExcludingNorthAndSouthAmericaMember 2023-07-01 2023-09-30 0000946563 rvp:SyringesMember rvp:NorthAndSouthAmericaExcludingUnitedStatesMember 2023-07-01 2023-09-30 0000946563 rvp:SyringesMember country:US 2023-07-01 2023-09-30 0000946563 rvp:OtherProductsMember rvp:OtherInternationalExcludingNorthAndSouthAmericaMember 2023-07-01 2023-09-30 0000946563 rvp:OtherProductsMember rvp:NorthAndSouthAmericaExcludingUnitedStatesMember 2023-07-01 2023-09-30 0000946563 rvp:OtherProductsMember country:US 2023-07-01 2023-09-30 0000946563 rvp:EasyPointNeedlesMember rvp:OtherInternationalExcludingNorthAndSouthAmericaMember 2023-07-01 2023-09-30 0000946563 rvp:EasyPointNeedlesMember country:US 2023-07-01 2023-09-30 0000946563 rvp:BloodCollectionProductsMember rvp:OtherInternationalExcludingNorthAndSouthAmericaMember 2023-07-01 2023-09-30 0000946563 rvp:BloodCollectionProductsMember country:US 2023-07-01 2023-09-30 0000946563 us-gaap:LicenseMember 2023-07-01 2023-09-30 0000946563 rvp:SyringesMember 2023-07-01 2023-09-30 0000946563 rvp:OtherProductsMember 2023-07-01 2023-09-30 0000946563 rvp:OtherInternationalExcludingNorthAndSouthAmericaMember 2023-07-01 2023-09-30 0000946563 rvp:NorthAndSouthAmericaExcludingUnitedStatesMember 2023-07-01 2023-09-30 0000946563 rvp:EasyPointNeedlesMember 2023-07-01 2023-09-30 0000946563 rvp:BloodCollectionProductsMember 2023-07-01 2023-09-30 0000946563 country:US 2023-07-01 2023-09-30 0000946563 rvp:SyringesMember rvp:OtherInternationalExcludingNorthAndSouthAmericaMember 2023-01-01 2023-09-30 0000946563 rvp:SyringesMember rvp:NorthAndSouthAmericaExcludingUnitedStatesMember 2023-01-01 2023-09-30 0000946563 rvp:SyringesMember country:US 2023-01-01 2023-09-30 0000946563 rvp:OtherProductsMember rvp:OtherInternationalExcludingNorthAndSouthAmericaMember 2023-01-01 2023-09-30 0000946563 rvp:OtherProductsMember rvp:NorthAndSouthAmericaExcludingUnitedStatesMember 2023-01-01 2023-09-30 0000946563 rvp:OtherProductsMember country:US 2023-01-01 2023-09-30 0000946563 rvp:EasyPointNeedlesMember rvp:OtherInternationalExcludingNorthAndSouthAmericaMember 2023-01-01 2023-09-30 0000946563 rvp:EasyPointNeedlesMember country:US 2023-01-01 2023-09-30 0000946563 rvp:BloodCollectionProductsMember rvp:OtherInternationalExcludingNorthAndSouthAmericaMember 2023-01-01 2023-09-30 0000946563 rvp:BloodCollectionProductsMember country:US 2023-01-01 2023-09-30 0000946563 us-gaap:LicenseMember 2023-01-01 2023-09-30 0000946563 rvp:SyringesMember 2023-01-01 2023-09-30 0000946563 rvp:OtherProductsMember 2023-01-01 2023-09-30 0000946563 rvp:OtherInternationalExcludingNorthAndSouthAmericaMember 2023-01-01 2023-09-30 0000946563 rvp:NorthAndSouthAmericaExcludingUnitedStatesMember 2023-01-01 2023-09-30 0000946563 rvp:EasyPointNeedlesMember 2023-01-01 2023-09-30 0000946563 rvp:BloodCollectionProductsMember 2023-01-01 2023-09-30 0000946563 country:US 2023-01-01 2023-09-30 0000946563 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2024-09-30 0000946563 srt:MinimumMember us-gaap:EquipmentMember 2024-09-30 0000946563 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2024-09-30 0000946563 srt:MaximumMember us-gaap:EquipmentMember 2024-09-30 0000946563 us-gaap:BuildingMember 2024-09-30 0000946563 us-gaap:BuildingImprovementsMember 2024-09-30 0000946563 rvp:SeriesTwoConvertibleClassBPreferredStockMember 2024-09-30 0000946563 rvp:SeriesThreeConvertibleClassBPreferredStockMember 2024-09-30 0000946563 rvp:SeriesTwoConvertibleClassBPreferredStockMember 2023-12-31 0000946563 rvp:SeriesThreeConvertibleClassBPreferredStockMember 2023-12-31 0000946563 us-gaap:PreferredClassBMember 2024-09-30 0000946563 us-gaap:PreferredClassBMember 2023-12-31 0000946563 us-gaap:PreferredClassBMember 2023-02-01 2023-02-28 0000946563 us-gaap:PreferredClassBMember 2022-02-01 2022-02-28 0000946563 us-gaap:PreferredClassBMember 2021-02-01 2021-02-28 0000946563 us-gaap:GeographicDistributionForeignMember 2024-09-30 0000946563 us-gaap:GeographicDistributionDomesticMember 2024-09-30 0000946563 us-gaap:GeographicDistributionForeignMember 2023-12-31 0000946563 us-gaap:GeographicDistributionDomesticMember 2023-12-31 0000946563 us-gaap:FairValueInputsLevel1Member us-gaap:MutualFundMember 2024-09-30 0000946563 us-gaap:FairValueInputsLevel1Member us-gaap:MunicipalBondsMember 2024-09-30 0000946563 us-gaap:FairValueInputsLevel1Member us-gaap:EquitySecuritiesMember 2024-09-30 0000946563 us-gaap:FairValueInputsLevel1Member 2024-09-30 0000946563 us-gaap:FairValueInputsLevel1Member us-gaap:MutualFundMember 2023-12-31 0000946563 us-gaap:FairValueInputsLevel1Member us-gaap:MunicipalBondsMember 2023-12-31 0000946563 us-gaap:FairValueInputsLevel1Member us-gaap:EquitySecuritiesMember 2023-12-31 0000946563 us-gaap:FairValueInputsLevel1Member 2023-12-31 0000946563 rvp:EasyPointNeedlesMember srt:ScenarioForecastMember 2024-10-01 2024-12-31 0000946563 rvp:SeriesTwoConvertibleClassBPreferredStockMember 2024-07-01 2024-07-31 0000946563 rvp:SeriesThreeConvertibleClassBPreferredStockMember 2024-07-01 2024-07-31 0000946563 rvp:SeriesTwoConvertibleClassBPreferredStockMember 2024-04-01 2024-04-30 0000946563 rvp:SeriesThreeConvertibleClassBPreferredStockMember 2024-04-01 2024-04-30 0000946563 rvp:SeriesTwoConvertibleClassBPreferredStockMember 2024-01-01 2024-01-31 0000946563 rvp:SeriesThreeConvertibleClassBPreferredStockMember 2024-01-01 2024-01-31 0000946563 rvp:SeriesTwoConvertibleClassBPreferredStockMember 2023-10-01 2023-10-31 0000946563 rvp:SeriesThreeConvertibleClassBPreferredStockMember 2023-10-01 2023-10-31 0000946563 rvp:SeriesTwoConvertibleClassBPreferredStockMember 2023-07-01 2023-07-31 0000946563 rvp:SeriesThreeConvertibleClassBPreferredStockMember 2023-07-01 2023-07-31 0000946563 rvp:SeriesTwoConvertibleClassBPreferredStockMember 2023-04-01 2023-04-30 0000946563 rvp:SeriesThreeConvertibleClassBPreferredStockMember 2023-04-01 2023-04-30 0000946563 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0000946563 us-gaap:RetainedEarningsMember 2024-01-01 2024-09-30 0000946563 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0000946563 us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0000946563 us-gaap:RoyaltyMember 2024-07-01 2024-09-30 0000946563 us-gaap:ProductMember 2024-07-01 2024-09-30 0000946563 us-gaap:RoyaltyMember 2024-01-01 2024-09-30 0000946563 us-gaap:ProductMember 2024-01-01 2024-09-30 0000946563 us-gaap:RoyaltyMember 2023-07-01 2023-09-30 0000946563 us-gaap:ProductMember 2023-07-01 2023-09-30 0000946563 us-gaap:RoyaltyMember 2023-01-01 2023-09-30 0000946563 us-gaap:ProductMember 2023-01-01 2023-09-30 0000946563 2023-01-01 2023-12-31 0000946563 rvp:SignificantCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0000946563 country:CN us-gaap:CostOfGoodsProductLineMember us-gaap:SupplierConcentrationRiskMember 2024-07-01 2024-09-30 0000946563 rvp:SignificantCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0000946563 country:CN us-gaap:CostOfGoodsProductLineMember us-gaap:SupplierConcentrationRiskMember 2024-01-01 2024-09-30 0000946563 rvp:SignificantCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0000946563 country:CN us-gaap:CostOfGoodsProductLineMember us-gaap:SupplierConcentrationRiskMember 2023-07-01 2023-09-30 0000946563 rvp:SignificantCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0000946563 country:CN us-gaap:CostOfGoodsProductLineMember us-gaap:SupplierConcentrationRiskMember 2023-01-01 2023-09-30 0000946563 2023-09-30 0000946563 2022-12-31 0000946563 rvp:TechnologyInvestmentAgreementMember 2020-07-01 2020-07-01 0000946563 us-gaap:GeographicDistributionDomesticMember 2024-01-01 2024-09-30 0000946563 rvp:EasyPointNeedlesMember 2024-02-05 2024-02-05 0000946563 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0000946563 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0000946563 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0000946563 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0000946563 rvp:SeriesThreeConvertibleClassBPreferredStockMember us-gaap:PreferredStockMember 2023-11-01 2023-11-30 0000946563 rvp:TechnologyInvestmentAgreementMember 2021-05-01 2021-05-31 0000946563 rvp:TechnologyInvestmentAgreementMember 2024-09-30 0000946563 rvp:TechnologyInvestmentAgreementMember 2023-09-30 0000946563 rvp:SeriesThreeConvertibleClassBPreferredStockMember us-gaap:PreferredStockMember 2023-11-30 0000946563 us-gaap:PreferredClassBMember 2020-12-31 0000946563 rvp:VanishPointAndEasyPointNeedlesMember 2023-01-01 2023-12-31 0000946563 country:CN us-gaap:CostOfGoodsProductLineMember us-gaap:SupplierConcentrationRiskMember 2024-09-13 2024-09-13 0000946563 2023-01-01 2023-09-30 0000946563 us-gaap:EquitySecuritiesMember 2024-09-30 0000946563 us-gaap:EquitySecuritiesMember 2023-12-31 0000946563 us-gaap:MutualFundMember 2024-09-30 0000946563 us-gaap:MunicipalBondsMember 2024-09-30 0000946563 us-gaap:MutualFundMember 2023-12-31 0000946563 us-gaap:MunicipalBondsMember 2023-12-31 0000946563 2024-09-30 0000946563 2023-12-31 0000946563 rvp:SeriesTwoThreeFourAndFiveConvertibleClassBPreferredStockMember 2021-06-01 2021-06-30 0000946563 us-gaap:PreferredClassBMember 2020-01-01 2020-12-31 0000946563 rvp:ThomasJShawMember 2023-07-01 2023-09-30 0000946563 2024-07-01 2024-09-30 0000946563 2023-07-01 2023-09-30 0000946563 2024-11-01 0000946563 2024-01-01 2024-09-30 xbrli:shares iso4217:USD xbrli:pure rvp:item rvp:stockholder rvp:customer iso4217:USD xbrli:shares

Table of Contents

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

FORM 10-Q

​

(Mark One)

​

☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

​

For the quarterly period ended September 30, 2024

​

or

​

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934

​

For the transition period from to

​

Commission file number: 001-16465

​

Retractable Technologies, Inc.

(Exact name of registrant as specified in its charter)

​

​

| ​ |
Texas |  | 75-2599762
(State or other jurisdiction of incorporation or organization) | ​ | (I.R.S. Employer Identification No.)
​ | ​ | ​
511 Lobo Lane | ​ | ​
Little Elm, Texas | ​ | 75068-5295
(Address of principal executive offices) | ​ | (Zip Code)

​

(972) 294-1010

(Registrant’s telephone number, including area code)

​

(Former name, former address, and former fiscal year, if changed since last report)

​

Securities registered pursuant to Section 12(b) of the Act:

​

​ | ​ | ​
Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Stock | RVP | NYSE American

​

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

​

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐

​

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and “emerging growth company” in Rule 12b-2 of the Exchange Act.

​

​ | ​ | ​ | ​
Large accelerated filer | ☐ | Accelerated filer | ☐
​ | ​ | ​ | ​
Non-accelerated filer | ☑ | Smaller reporting company | ☑
​ | ​ | Emerging growth company | ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

​

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑

​

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY

PROCEEDINGS DURING THE PRECEDING FIVE YEARS:

​

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13, or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes ◻ No ◻

​

APPLICABLE ONLY TO CORPORATE ISSUERS

​

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 29,937,159 shares of Common Stock outstanding, excluding 4,087,145 treasury shares, on November 1, 2024.

​

​

​

​

Table of Contents

RETRACTABLE TECHNOLOGIES, INC.

FORM 10-Q

For the Quarterly Period Ended September 30, 2024

TABLE OF CONTENTS

​

​ | PART I – FINANCIAL INFORMATION | ​ | ​
​ | ​ | ​ | ​
Item 1. | Financial Statements |  | 1
​ | CONDENSED BALANCE SHEETS | ​ | 1
​ | CONDENSED STATEMENTS OF OPERATIONS | ​ | 2
​ | CONDENSED STATEMENTS OF CASH FLOWS | ​ | 3
​ | CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY | ​ | 4
​ | NOTES TO CONDENSED FINANCIAL STATEMENTS | ​ | 5
Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | ​ | 17
Item 3. | Quantitative and Qualitative Disclosures About Market Risk | ​ | 22
Item 4. | Controls and Procedures | ​ | 22
​ | ​ | ​ | ​
​ | PART II—OTHER INFORMATION | ​ | ​
​ | ​ | ​ | ​
Item 1. | Legal Proceedings | ​ | 22
Item 1A. | Risk Factors | ​ | 22
Item 5. | Other Information | ​ | 22
Item 6. | Exhibits | ​ | 23
SIGNATURES | ​ | 23

​

​

​

​

​

​

Table of Contents

PART I—FINANCIAL INFORMATION

Item 1.Financial Statements.

RETRACTABLE TECHNOLOGIES, INC.

CONDENSED BALANCE SHEETS

(unaudited)

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | September 30, 2024 |  | December 31, 2023
ASSETS | ​ | ​ | ​ | ​ | ​ | ​
Current assets: | ​ | ​ | ​ | ​ | ​ | ​
Cash and cash equivalents | ​ | $ | 3,917,246 | ​ | $ | 12,667,550
Accounts receivable, net | ​ |  | 8,674,774 | ​ |  | 10,671,721
Investments in debt and equity securities, at fair value | ​ | ​ | 32,782,319 | ​ | ​ | 34,621,213
Inventories | ​ |  | 21,301,008 | ​ |  | 17,581,368
Income taxes receivable | ​ | ​ | 1,111,851 | ​ | ​ | 1,155,077
Other current assets | ​ |  | 968,949 | ​ |  | 952,668
Total current assets | ​ |  | 68,756,147 | ​ |  | 77,649,597
​ | ​ | ​ | ​ | ​ | ​ | ​
Property, plant, and equipment, net | ​ |  | 88,936,910 | ​ |  | 93,478,521
Deferred tax asset | ​ | ​ | — | ​ | ​ | 8,392,030
Other assets | ​ |  | 114,803 | ​ |  | 152,064
Total assets | ​ | $ | 157,807,860 | ​ | $ | 179,672,212
​ | ​ | ​ | ​ | ​ | ​ | ​
LIABILITIES AND STOCKHOLDERS’ EQUITY | ​ | ​ | ​ | ​ | ​ | ​
Current liabilities: | ​ | ​ | ​ | ​ | ​ | ​
Accounts payable | ​ | $ | 3,251,331 | ​ | $ | 4,779,035
Current portion of long-term debt | ​ |  | 325,155 | ​ |  | 303,991
Accrued compensation | ​ |  | 809,937 | ​ |  | 865,105
Dividends payable | ​ |  | 1,417,437 | ​ |  | 1,417,437
Accrued royalties to shareholder | ​ |  | 884,570 | ​ |  | 1,376,555
Other accrued liabilities | ​ |  | 1,325,080 | ​ |  | 630,571
Income taxes payable | ​ |  | 5,864 | ​ |  | 4,802
Total current liabilities | ​ |  | 8,019,374 | ​ |  | 9,377,496
​ | ​ | ​ | ​ | ​ | ​ | ​
Other long-term liabilities | ​ | ​ | 65,344,155 | ​ | ​ | 69,773,538
Long-term debt, net of current maturities | ​ |  | 986,750 | ​ |  | 1,233,519
Total liabilities | ​ |  | 74,350,279 | ​ |  | 80,384,553
​ | ​ | ​ | ​ | ​ | ​ | ​
Commitments and contingencies – see Note 10 | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​
Stockholders’ equity: | ​ | ​ | ​ | ​ | ​ | ​
Preferred stock, $1 par value: | ​ | ​ | ​ | ​ | ​ | ​
Class B; authorized: 5,000,000 shares | ​ | ​ | ​ | ​ | ​ | ​
Series II, Class B | ​ |  | 156,200 | ​ |  | 156,200
Series III, Class B | ​ |  | 74,245 | ​ |  | 74,245
Common Stock, no par value | ​ |  | — | ​ |  | —
Additional paid-in capital | ​ |  | 73,160,333 | ​ |  | 73,160,333
Retained earnings | ​ |  | 22,955,481 | ​ |  | 38,785,559
Common stock in treasury – at cost | ​ | ​ | (12,888,678) | ​ | ​ | (12,888,678)
Total stockholders’ equity | ​ |  | 83,457,581 | ​ |  | 99,287,659
Total liabilities and stockholders’ equity | ​ | $ | 157,807,860 | ​ | $ | 179,672,212

​

See accompanying notes to condensed unaudited financial statements

​

1

Table of Contents

RETRACTABLE TECHNOLOGIES, INC.

CONDENSED STATEMENTS OF OPERATIONS

(unaudited)

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months | ​ | Three Months | ​ | Nine Months | ​ | Nine Months | ​
​ |  | September 30, 2024 |  | September 30, 2023 |  | September 30, 2024 |  | September 30, 2023 | ​
Sales, net | ​ | $ | 10,346,857 | ​ | $ | 10,335,031 | ​ | $ | 23,975,584 | ​ | $ | 29,307,413 | ​
Cost of sales: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Cost of manufactured product | ​ |  | 9,477,097 | ​ |  | 5,219,962 | ​ |  | 20,379,228 | ​ |  | 19,522,722 | ​
Royalty expense to shareholder | ​ |  | 884,570 | ​ |  | 794,388 | ​ |  | 2,130,161 | ​ |  | 2,217,575 | ​
Total cost of sales | ​ |  | 10,361,667 | ​ |  | 6,014,350 | ​ |  | 22,509,389 | ​ |  | 21,740,297 | ​
Gross profit (loss) | ​ |  | (14,810) | ​ |  | 4,320,681 | ​ |  | 1,466,195 | ​ |  | 7,567,116 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating expenses: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Sales and marketing | ​ |  | 1,749,123 | ​ |  | 1,368,112 | ​ |  | 4,658,465 | ​ |  | 4,263,735 | ​
Research and development | ​ |  | 174,695 | ​ |  | 150,957 | ​ |  | 516,050 | ​ |  | 419,475 | ​
General and administrative | ​ |  | 3,197,116 | ​ |  | 3,737,479 | ​ |  | 10,176,367 | ​ |  | 11,592,965 | ​
Total operating expenses | ​ |  | 5,120,934 | ​ |  | 5,256,548 | ​ |  | 15,350,882 | ​ |  | 16,276,175 | ​
Loss from operations | ​ |  | (5,135,744) | ​ |  | (935,867) | ​ |  | (13,884,687) | ​ |  | (8,709,059) | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Other income - TIA | ​ | ​ | 1,469,688 | ​ | ​ | 1,447,975 | ​ | ​ | 4,429,383 | ​ | ​ | 4,479,773 | ​
Unrealized gain (loss) on debt and equity securities | ​ | ​ | 1,449,825 | ​ | ​ | (6,538,568) | ​ | ​ | 1,402,660 | ​ | ​ | (11,298,207) | ​
Gain on sale of equity securities | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 5,574,791 | ​
Interest and other income | ​ |  | 293,550 | ​ |  | 768,863 | ​ |  | 855,387 | ​ |  | 1,197,329 | ​
Interest expense | ​ |  | (30,489) | ​ |  | (36,087) | ​ |  | (95,789) | ​ |  | (117,110) | ​
Loss before income taxes | ​ |  | (1,953,170) | ​ |  | (5,293,684) | ​ |  | (7,293,046) | ​ |  | (8,872,483) | ​
Provision (benefit) for income taxes | ​ |  | (31,181) | ​ |  | (1,233,188) | ​ |  | 8,364,200 | ​ |  | (1,934,393) | ​
Net loss | ​ |  | (1,921,989) | ​ |  | (4,060,496) | ​ |  | (15,657,246) | ​ |  | (6,938,090) | ​
Preferred Stock dividend requirements | ​ |  | (57,611) | ​ |  | (58,111) | ​ |  | (172,832) | ​ |  | (174,335) | ​
Net loss applicable to common shareholders | ​ | $ | (1,979,600) | ​ | $ | (4,118,607) | ​ | $ | (15,830,078) | ​ | $ | (7,112,425) | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Basic loss per share | ​ | $ | (0.07) | ​ | $ | (0.14) | ​ | $ | (0.53) | ​ | $ | (0.24) | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Diluted loss per share | ​ | $ | (0.07) | ​ | $ | (0.14) | ​ | $ | (0.53) | ​ | $ | (0.24) | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Weighted average common shares outstanding: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Basic | ​ |  | 29,937,159 | ​ |  | 29,937,159 | ​ |  | 29,937,159 | ​ |  | 29,937,159 | ​
Diluted | ​ |  | 29,937,159 | ​ |  | 29,937,159 | ​ |  | 29,937,159 | ​ |  | 29,937,159 | ​

​

See accompanying notes to condensed unaudited financial statements

​

2

Table of Contents

RETRACTABLE TECHNOLOGIES, INC.

CONDENSED STATEMENTS OF CASH FLOWS

(unaudited)

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Nine Months | ​ | Nine Months | ​
​ | ​ | Ended | ​ | Ended | ​
​ |  | September 30, 2024 |  | September 30, 2023 | ​
Cash flows from operating activities | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net loss | ​ | $ | (15,657,246) | ​ | $ | (6,938,090) | ​
Adjustments to reconcile net loss to net cash from operating activities: | ​ | ​ | ​ | ​ | ​ | ​ | ​
Depreciation and amortization | ​ |  | 5,683,496 | ​ |  | 5,826,203 | ​
Net unrealized (gain) loss on investments | ​ | ​ | (1,402,660) | ​ | ​ | 11,298,207 | ​
Realized gain on investments | ​ | ​ | — | ​ | ​ | (5,574,791) | ​
Accreted interest | ​ | ​ | — | ​ | ​ | 9,157 | ​
Bond amortization | ​ | ​ | (763) | ​ | ​ | — | ​
Deferred taxes | ​ | ​ | 8,392,030 | ​ | ​ | (2,014,939) | ​
Provision for credit losses | ​ |  | 414,598 | ​ |  | 452,547 | ​
Net realizable value inventory adjustment | ​ | ​ | (9,466) | ​ | ​ | 172,203 | ​
Other income - TIA | ​ | ​ | (4,429,383) | ​ | ​ | (4,479,773) | ​
(Increase) decrease in operating assets: | ​ | ​ | ​ | ​ | ​ | ​ | ​
Accounts receivable | ​ |  | 1,582,349 | ​ |  | (3,797,674) | ​
Inventories | ​ |  | (3,710,174) | ​ |  | (1,954,988) | ​
Other current assets | ​ |  | (16,281) | ​ |  | 167,166 | ​
Income taxes receivable | ​ | ​ | 43,226 | ​ | ​ | 9,475,906 | ​
Other assets | ​ | ​ | 37,261 | ​ | ​ | 25,008 | ​
Increase (decrease) in operating liabilities: | ​ | ​ | ​ | ​ | ​ | ​ | ​
Accounts payable | ​ |  | (1,527,704) | ​ |  | (3,011,574) | ​
Accrued liabilities | ​ |  | 147,356 | ​ |  | 1,241,700 | ​
Income taxes payable | ​ |  | 1,062 | ​ |  | (23,263) | ​
Net cash from (used) operating activities | ​ |  | (10,452,299) | ​ |  | 873,005 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Cash flows from investing activities | ​ | ​ | ​ | ​ | ​ | ​ | ​
Purchase of property, plant, and equipment | ​ |  | (1,141,885) | ​ |  | (699,283) | ​
Purchase of debt and equity securities | ​ | ​ | (757,683) | ​ | ​ | (68,287,428) | ​
Proceeds from the sales of debt and equity securities | ​ | ​ | 4,000,000 | ​ | ​ | 58,572,186 | ​
Net cash from (used) investing activities | ​ |  | 2,100,432 | ​ |  | (10,414,525) | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Cash flows from financing activities | ​ | ​ | ​ | ​ | ​ | ​ | ​
Repayments of long-term debt | ​ |  | (225,605) | ​ |  | (209,789) | ​
Proceeds from Technology Investment Agreement (TIA) | ​ | ​ | — | ​ | ​ | 2,563,229 | ​
Payment of preferred stock repurchase payable | ​ | ​ | — | ​ | ​ | (1,101,110) | ​
Payment of preferred stock dividends | ​ |  | (172,832) | ​ |  | (174,333) | ​
Net cash from (used) financing activities | ​ |  | (398,437) | ​ |  | 1,077,997 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net decrease in cash and cash equivalents | ​ |  | (8,750,304) | ​ |  | (8,463,523) | ​
Cash and cash equivalents at: | ​ | ​ | ​ | ​ | ​ | ​ | ​
Beginning of period | ​ |  | 12,667,550 | ​ |  | 19,721,345 | ​
End of period | ​ | $ | 3,917,246 | ​ | $ | 11,257,822 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Supplemental schedule of cash flow information: | ​ | ​ | ​ | ​ | ​ | ​ | ​
Interest paid | ​ | $ | 94,691 | ​ | $ | 71,867 | ​
Income taxes paid | ​ | $ | — | ​ | ​ | — | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Supplemental schedule of noncash investing and financing activities: | ​ | ​ | ​ | ​ | ​ | ​ | ​
Preferred dividends declared, not paid | ​ | $ | 57,611 | ​ | $ | 57,611 | ​

​

See accompanying notes to condensed unaudited financial statements

​

3

Table of Contents

RETRACTABLE TECHNOLOGIES, INC.

CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

(unaudited)

​

​

The following shows the changes in stockholders’ equity for the three-month period ended September 30, 2024:

​

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ | ​ |  | Series II |  | Series III |  | ​ | ​ |  | ​ | ​ | ​ | ​ |  | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | Class B | ​ | Class B | ​ | Additional | ​ | ​ | ​ | ​ | Treasury | ​ | ​ | ​
​ | ​ | Common | ​ | Preferred | ​ | Preferred | ​ | Paid-In | ​ | Retained | ​ | Stock – | ​ | ​ | ​
​ | ​ | Stock | ​ | Stock | ​ | Stock | ​ | Capital | ​ | Earnings | ​ | at cost | ​ | Total
Balance at June 30, 2024 | ​ | $ | — | ​ | $ | 156,200 | ​ | $ | 74,245 | ​ | $ | 73,160,333 | ​ | $ | 24,935,081 | ​ | $ | (12,888,678) | ​ | $ | 85,437,181
Dividends | ​ |  | — | ​ |  | — | ​ |  | — | ​ |  | — | ​ |  | (57,611) | ​ |  | — | ​ |  | (57,611)
Net Loss | ​ |  | — | ​ |  | — | ​ |  | — | ​ |  | — | ​ |  | (1,921,989) | ​ |  | — | ​ |  | (1,921,989)
Balance at September 30, 2024 | ​ | $ | — | ​ | $ | 156,200 | ​ | $ | 74,245 | ​ | $ | 73,160,333 | ​ | $ | 22,955,481 | ​ | $ | (12,888,678) | ​ | $ | 83,457,581

​

​

The following shows the changes in stockholders’ equity for the three-month period ended September 30, 2023:

​

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ | ​ |  | Series II |  | Series III |  | ​ | ​ |  | ​ | ​ | ​ | ​ |  | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | Class B | ​ | Class B | ​ | Additional | ​ | ​ | ​ | ​ | Treasury | ​ | ​ | ​
​ | ​ | Common | ​ | Preferred | ​ | Preferred | ​ | Paid-In | ​ | Retained | ​ | Stock – | ​ | ​ | ​
​ | ​ | Stock | ​ | Stock | ​ | Stock | ​ | Capital | ​ | Earnings | ​ | at cost | ​ | Total
Balance at June 30, 2023 | ​ | $ | — | ​ | $ | 156,200 | ​ | $ | 76,245 | ​ | $ | 73,164,501 | ​ | $ | 43,034,723 | ​ | $ | (12,888,678) | ​ | $ | 103,542,991
Dividends | ​ |  | — | ​ |  | — | ​ |  | — | ​ |  | — | ​ |  | (58,111) | ​ | ​ | — | ​ |  | (58,111)
Net Loss | ​ |  | — | ​ |  | — | ​ |  | — | ​ |  | — | ​ |  | (4,060,496) | ​ | ​ | — | ​ |  | (4,060,496)
Balance at September 30, 2023 | ​ | $ | — | ​ | $ | 156,200 | ​ | $ | 76,245 | ​ | $ | 73,164,501 | ​ | $ | 38,916,116 | ​ | $ | (12,888,678) | ​ | $ | 99,424,384

​

​

The following shows the changes in stockholders’ equity for the nine-month period ended September 30, 2024:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ | ​ |  | Series II |  | Series III |  | ​ | ​ |  | ​ | ​ | ​ | ​ |  | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | Class B | ​ | Class B | ​ | Additional | ​ | ​ | ​ | ​ | Treasury | ​ | ​ | ​
​ | ​ | Common | ​ | Preferred | ​ | Preferred | ​ | Paid-In | ​ | Retained | ​ | Stock – | ​ | ​ | ​
​ | ​ | Stock | ​ | Stock | ​ | Stock | ​ | Capital | ​ | Earnings | ​ | at cost | ​ | Total
Balance at December 31, 2023 | ​ | $ | — | ​ | $ | 156,200 | ​ | $ | 74,245 | ​ | $ | 73,160,333 | ​ | $ | 38,785,559 | ​ | $ | (12,888,678) | ​ | $ | 99,287,659
Dividends | ​ |  | — | ​ |  | — | ​ |  | — | ​ |  | — | ​ | ​ | (172,832) | ​ | ​ | — | ​ | ​ | (172,832)
Net Loss | ​ |  | — | ​ |  | — | ​ |  | — | ​ |  | — | ​ | ​ | (15,657,246) | ​ | ​ | — | ​ | ​ | (15,657,246)
Balance at September 30, 2024 | ​ | $ | — | ​ | $ | 156,200 | ​ | $ | 74,245 | ​ | $ | 73,160,333 | ​ | $ | 22,955,481 | ​ | $ | (12,888,678) | ​ | $ | 83,457,581

​

​

The following shows the changes in stockholders’ equity for the nine-month period ended September 30, 2023:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ | ​ |  | Series II |  | Series III |  | ​ | ​ |  | ​ | ​ | ​ | ​ |  | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | Class B | ​ | Class B | ​ | Additional | ​ | ​ | ​ | ​ | Treasury | ​ | ​ | ​
​ | ​ | Common | ​ | Preferred | ​ | Preferred | ​ | Paid-In | ​ | Retained | ​ | Stock – | ​ | ​ | ​
​ | ​ | Stock | ​ | Stock | ​ | Stock | ​ | Capital | ​ | Earnings | ​ | at cost | ​ | Total
Balance at December 31, 2022 | ​ | $ | — | ​ | $ | 156,200 | ​ | $ | 76,245 | ​ | $ | 73,164,501 | ​ | $ | 46,028,541 | ​ | $ | (12,888,678) | ​ | $ | 106,536,809
Dividends | ​ |  | — | ​ |  | — | ​ |  | — | ​ | ​ | — | ​ | ​ | (174,335) | ​ |  | — | ​ |  | (174,335)
Net Loss | ​ |  | — | ​ |  | — | ​ |  | — | ​ | ​ | — | ​ | ​ | (6,938,090) | ​ |  | — | ​ |  | (6,938,090)
Balance at September 30, 2023 | ​ | $ | — | ​ | $ | 156,200 | ​ | $ | 76,245 | ​ | $ | 73,164,501 | ​ | $ | 38,916,116 | ​ | $ | (12,888,678) | ​ | $ | 99,424,384

​

​

​

​

​

4

Table of Contents

​

​

RETRACTABLE TECHNOLOGIES, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(unaudited)

1. BUSINESS OF THE COMPANY AND BASIS OF PRESENTATION

Business of the Company

Retractable Technologies, Inc. (the “Company”) was incorporated in Texas on May 9, 1994, and designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession. The Company began to develop its manufacturing operations in 1995. The Company’s manufacturing and administrative facilities are located in Little Elm, Texas. The Company’s products are the VanishPoint® 0.5mL insulin syringe; 1mL tuberculin, insulin, and allergy antigen syringes; 0.5mL, 1mL, 2mL, 3mL, 5mL, and 10mL syringes; the blood collection tube holder; the EasyPoint® blood collection tube holder with needle; the small diameter tube adapter; the allergy tray; the IV safety catheter; the Patient Safe® syringes; the Patient Safe® Luer Cap; the VanishPoint® Blood Collection Set; and the EasyPoint® needle as well as a standard 3mL syringe packaged with an EasyPoint® needle. The Company also sells VanishPoint® autodisable syringes in the international market in addition to the Company’s other products.

Basis of presentation

The accompanying condensed financial statements are unaudited and, in the opinion of Management, reflect all adjustments that are necessary for a fair presentation of the financial position and results of operations for the periods presented. All such adjustments are of a normal and recurring nature. The results of operations for the periods presented are not necessarily indicative of the results to be expected for the entire year. The unaudited condensed financial statements should be read in conjunction with the financial statement disclosures contained in the Company’s audited financial statements incorporated into its Form 10-K filed on March 29, 2024 for the year ended December 31, 2023.

​

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Accounting estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires Management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ significantly from those estimates. The amount reported as a contractual allowance for rebates involves examination of past historical trends related to sales to customers and the related credits issued once contractual obligations of the customers have been met. The establishment of a liability for future claims of rebates against sales in the current period requires that the Company has an understanding of the relevant sales with respect to product categories, sales distribution channels, and the likelihood of contractual obligations being satisfied.

Cash and cash equivalents

For purposes of reporting cash flows, cash and cash equivalents include cash, money market accounts, and investments with original maturities of three months or less.

Accounts receivable

The Company records trade receivables when revenue is recognized. No product has been consigned to customers. The Company’s allowance for credit losses is primarily determined by review of specific trade receivables based on historical collection rates and specific knowledge regarding the current creditworthiness of the customers. Those

5

Table of Contents

accounts that are doubtful of collection are included in the allowance. The Company considers historical experience, the current economic environment, customer credit ratings or bankruptcies, legal disputes, collections on past due amounts, pricing discrepancies, and reasonable and supportable forecasts to develop its allowance for credit losses. Management reviews these factors quarterly to determine if any adjustments are needed to the allowance. Trade receivables are charged off when there is certainty as to their being uncollectible. Trade receivables are considered delinquent when payment has not been made within contract terms. The allowance for credit losses was $597 thousand and $891 thousand as of September 30, 2024 and December 31, 2023, respectively.

The Company requires certain customers to make a prepayment prior to beginning production or shipment of their order. Customers may apply such prepayments to their outstanding invoices or pay the invoice and continue to carry forward the deposit for future orders. Such amounts are included in Other accrued liabilities on the Condensed Balance Sheets and are shown in Note 6, Other Accrued Liabilities.

The Company records an allowance for estimated returns as a reduction to Accounts receivable and Gross sales. Historically, returns have been insignificant.

Inventories

Inventories are valued at the lower of cost or net realizable value, with cost being determined using actual average cost. The Company compares the average cost to the net realizable value and records the lower value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The Company recorded $9.5 thousand and $101 thousand lower of cost or net realizable value inventory adjustment associated with the VanishPoint® 3mL and EasyPoint® needle product segments as of September 30, 2024 and December 31, 2023, respectively.

Management considers such factors as the amount of inventory on hand and in the distribution channel, estimated time to sell such inventory, the shelf life of inventory, and current market conditions when determining excess or obsolete inventories. Once inventory items are deemed to be either excess or obsolete, they are written down to their net realizable value.

Investments in debt and equity securities

The Company holds mutual funds, debt, and equity securities as investments. These assets are held as trading securities and are carried at fair value as of the date of the Condensed Balance Sheets. Net unrealized and realized gains or losses on these investments are reflected separately on the Condensed Statements of Operations. Realized gains or losses on investments are recognized using the specific identification method.

Property, plant, and equipment

Property, plant, and equipment are stated at cost less accumulated depreciation. Expenditures for maintenance and repairs are charged to operations as incurred. Cost includes major expenditures for improvements and replacements which extend useful lives or increase capacity and interest costs associated with significant capital additions. Gains or losses from disposals are included in Interest and other income.

The Company's property, plant, and equipment primarily consist of buildings, land, assembly equipment, molding machines, molds, office equipment, furniture, and fixtures. Depreciation and amortization are calculated using the straight-line method over the following useful lives:

​

​ | ​ | ​
Production equipment |  | 3 to 13 years
Office furniture and equipment |  | 3 to 10 years
Buildings |  | 39 years
Building improvements |  | 15 years

​

6

Table of Contents

Long-lived assets

The Company assesses the recoverability of long-lived assets using an assessment of the estimated undiscounted future cash flows related to such assets. In the event that assets are found to be carried at amounts which are in excess of estimated gross future cash flows, the assets will be adjusted for impairment to a level commensurate with fair value determined using a discounted cash flow analysis or appraised values of the underlying assets.

Fair value measurements

For assets and liabilities that are measured using quoted prices in active markets, total fair value is the published market price per unit multiplied by the number of units held without consideration of transaction costs. Assets and liabilities that are measured using significant other observable inputs are valued by reference to similar assets or liabilities, adjusted for contract restrictions and other terms specific to that asset or liability. For these items, a significant portion of fair value is derived by reference to quoted prices of similar assets or liabilities in active markets. For all remaining assets and liabilities, fair value is derived using a fair value model, such as a discounted cash flow model or Black-Scholes model.

Financial instruments

The Company estimates the fair value of financial instruments through the use of public market prices, quotes from financial institutions, and other available information. Judgment is required in interpreting data to develop estimates of fair value and, accordingly, amounts are not necessarily indicative of the amounts that could be realized in a current market exchange. Short-term financial instruments, including cash and cash equivalents, accounts receivable, accounts payable, and other liabilities, consist primarily of instruments without extended maturities, the fair value of which, based on Management's estimates, equals their recorded values. Investments in debt and equity securities consist primarily of individual equity securities and mutual funds and are reported at their fair value based upon quoted prices in active markets. The fair value of long-term liabilities, based on Management’s estimates, approximates their reported values.

Concentration risks

The Company’s financial instruments exposed to concentrations of credit risk consist primarily of cash, cash equivalents, certificates of deposit, exchange-traded and closed-end funds, mutual funds, equity securities, and accounts receivable. Cash balances, some of which exceed federally insured limits, are maintained in financial institutions; however, Management believes the institutions are of high credit quality. The Company assesses market risk in equity securities through consultation with its outside investment advisors. Management is responsible for directing investment activity based on current economic conditions. The majority of accounts receivable are due from companies which are well-established entities. Management considers any exposure from concentrations of credit risks to be limited.

The following table reflects our significant customers for the three-month and nine-month periods ended September 30, 2024 and 2023:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | ​ | Three Months Ended | ​ | ​ | Nine Months Ended | ​ | ​ | Nine Months Ended | ​
​ |  | September 30, 2024 |  | ​ | September 30, 2023 |  | ​ | September 30, 2024 |  | ​ | September 30, 2023 | ​
Number of significant customers |  | ​ | 2 |  | ​ | ​ | 3 |  | ​ | ​ | 3 |  | ​ | ​ | 3 |
Aggregate dollar amount of net sales to significant customers | ​ | $ | 5.5 | million | ​ | ​ | $ | 5.7 | million | ​ | ​ | $ | 12.8 | million | ​ | ​ | $ | 14.3 | million | ​
Percentage of net sales to significant customers | ​ | ​ | 53.2% | ​ | ​ | ​ | 55.0% | ​ | ​ | ​ | 53.4% | ​ | ​ | ​ | 49.0% | ​

​

The Company manufactures some of its products in Little Elm, Texas as well as utilizing manufacturers in China. The Company obtained 90% of its products in the first nine months of both 2024 and 2023 from its Chinese manufacturers. Purchases from Chinese manufacturers aggregated 87.3% and 91% of products in the third quarter

7

Table of Contents

of 2024 and 2023, respectively. In the event that the Company becomes unable to purchase products from its Chinese manufacturers, the Company may need to find an alternate manufacturer for its blood collection set, EasyPoint® blood collection tube holder with needle, IV catheter, Patient Safe® syringe, 0.5mL insulin syringe, 0.5mL autodisable syringe, and 2mL, 5mL, and 10mL syringes, and would increase domestic production for the 1mL and 3mL syringes and EasyPoint® needles.

On September 13, 2024, the Office of the U.S. Trade Representative (“USTR”) revealed final adjustments to increase tariffs on certain goods imported from China under Section 301 of the Trade Act of 1974. Among those products included were syringes and needles, at a rate of 100%. As noted above, for the first nine months of 2024, 90% of the products the Company obtained were purchased from our manufacturers in China, most of which are impacted by the tariffs. The adjusted tariffs were effective on September 27, 2024. Tariffs are expected to have a material impact to the Company’s results of operations and financial position. The Company is working to lessen the financial impact of the tariffs, including shifting a larger portion of manufacturing of 1mL, 3mL, and EasyPoint® needles to its domestic manufacturing facility.

Revenue recognition

The Company recognizes revenue when control of performance obligations passes to the customer, generally when the product ships. Payments from customers with approved credit terms are typically due 30 days from the invoice date. Under certain contracts, revenue is recorded on the basis of sales price to distributors, less contractual pricing allowances. Contractual pricing allowances consist of: (i) rebates granted to distributors who provide tracking reports which show, among other things, the facility that purchased the products, and (ii) a provision for estimated contractual pricing allowances for products for which the Company has not received tracking reports. When rebates are issued, they are applied against the customer’s receivable balance. Distributors receive a rebate for the difference between the Wholesale Acquisition Cost and the appropriate contract price as reflected on a tracking report provided by the distributor to the Company. If product is sold by a distributor to an entity that has no contract, there is a standard rebate (lower than a contracted rebate) given to the distributor. One of the purposes of the rebate is to encourage distributors to submit tracking reports to the Company. The provision for contractual pricing allowances is recognized in the period the related sales are recognized and is reviewed at the end of each quarter and adjusted for changes in levels of products for which there is no tracking report. Additionally, if it becomes clear that tracking reports will not be provided by individual distributors, the provision is further adjusted. The estimated contractual allowance is included in Accounts payable in the Condensed Balance Sheets and deducted from Revenues in the Condensed Statements of Operations. Accounts payable included estimated contractual allowances for $1.8 million and $2.2 million as of September 30, 2024 and December 31, 2023, respectively. The terms and conditions of contractual pricing allowances are governed by contracts between the Company and its distributors. Revenue for shipments directly to end-users is recognized when title and risk of ownership pass from the Company. End-users do not receive any contractual allowances on their purchases. Any product shipped or distributed for evaluation purposes is expensed.

The Company provides product warranties that: i) the products are fit for medical use as generally defined within the boundaries of United States FDA approval; ii) the products are not defective; and iii) the products will conform to the descriptions set forth in their respective labeling, provided that they are used in accordance with such labeling and the Company’s written directions for use. The Company has historically not incurred significant warranty claims.

The Company’s domestic return policy provides that a customer may return incorrect shipments within 10 days following arrival at the distributor’s facility. In all such cases, the distributor must obtain an authorization code from the Company and affix the code to the returned product. The Company’s domestic return policy also generally provides that a customer may return product that is overstocked. Overstocking returns are limited to two times in each 12-month period up to 1% of distributor’s total purchase of products for the prior 12-month period. All product overstocks and returns are subject to inspection and acceptance by the Company. The Company has not historically incurred significant returns.

On February 5, 2024, the Company initiated a voluntary recall of its EasyPoint Needle lot number K220402 which was shipped within the U.S. between July 20, 2022 and September 20, 2023. The Company shipped 477,600 units of

8

Table of Contents

the products into the market and is working with customers and distributors to determine how many of the units remain unused and subject to the recall. The recall is due to the possible detachment of the needle cannula from the needle holder, which could result in serious injury. The Company has advised its customers and distributors to review their inventory for the affected products, segregate and quarantine the affected products, discontinue any distribution of the affected products, inform all personnel not to use the affected products, and report and return remaining inventory to the Company. The Company submitted a Removal Report with the U.S. Food and Drug Administration and has continued to provide monthly updates. The estimated time for the completion of the recall is December 31, 2024. The Company estimates that the potential expense related to the recall is approximately $116 thousand.

The Company’s international distribution agreements generally do not provide for any returns.

The Company requires certain customers to pay in advance of product shipment. Such prepayments from customers are recorded in Other accrued liabilities and are generally recognized as revenue upon shipment of the product.

The Company periodically recognizes revenue from licensing agreements of its intellectual property. Such licensing agreements provide licensee with right to use the Company’s intellectual property. The Company accounts for revenue generated under these licensing agreements in accordance with ASC 606. A license may be perpetual or time limited in its application. The Company has concluded that its licensing agreement is distinct as the customer can benefit from the license on their own. In accordance with ASC 606, the licensing agreement is considered functional as it is without professional services, updates and technical support. The Company has determined the current licensing agreement is sales-based or usage-based as defined in ASC 606. In accordance with ASC 606, the Company recognizes revenue from sales-based or usage-based license at the later of a) subsequent sale or usage occurrence or b) the performance obligation to which some or all of the sales-based or usage-based royalty has been allocated has been satisfied (or partially satisfied). The Company recognized $38 thousand and $227 thousand in licensing fees for the three and nine months ended September 30, 2024. No licensing fees were recognized for the three and nine months ended September 30, 2023. If the Company licenses its products for sale and the customers of the sublicensee are not known to the Company, the Company is obligated to pay Thomas J. Shaw, the owner of certain patented technology, fifty percent (50%) of such revenue pursuant to the terms of the Technology License Agreement between the Company and Mr. Shaw.

Disaggregated information of revenue recognized from contracts with customers and licensing fees recognized are as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | For the three months ended September 30, 2024:
​ |  | ​ | ​ |  | Blood |  | ​ | ​ |  | ​ | ​ |  | Total
​ | ​ | ​ | ​ | ​ | Collection | ​ | EasyPoint® | ​ | Other | ​ | Product
Geographic Segment | ​ | Syringes | ​ | Products | ​ | Needles | ​ | Products | ​ | Sales
U.S. sales | ​ | $ | 4,470,036 | ​ | $ | 290,926 | ​ | $ | 4,860,327 | ​ | $ | 7,319 | ​ | $ | 9,628,608
North and South America sales (excluding U.S.) | ​ |  | 569,970 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ |  | 569,970
Other international sales | ​ |  | 132,817 | ​ | ​ | 7,790 | ​ | ​ | 3,572 | ​ | ​ | 4,100 | ​ |  | 148,279
Total | ​ | $ | 5,172,823 | ​ | $ | 298,716 | ​ | $ | 4,863,899 | ​ | $ | 11,419 | ​ | $ | 10,346,857

​

9

Table of Contents

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | For the three months ended September 30, 2023:
​ |  | ​ | ​ |  | Blood |  | ​ | ​ |  | ​ | ​ |  | Total
​ | ​ | ​ | ​ | ​ | Collection | ​ | EasyPoint® | ​ | Other | ​ | Product
Geographic Segment | ​ | Syringes | ​ | Products | ​ | Needles | ​ | Products | ​ | Sales
U.S. sales | ​ | $ | 6,439,220 | ​ | $ | 379,135 | ​ | $ | 2,566,161 | ​ | $ | 8,221 | ​ | $ | 9,392,737
North and South America sales (excluding U.S.) | ​ |  | 825,480 | ​ |  | — | ​ |  | — | ​ |  | 14,250 | ​ |  | 839,730
Other international sales | ​ |  | 87,694 | ​ |  | 10,920 | ​ |  | 3,800 | ​ |  | 150 | ​ |  | 102,564
Total | ​ | $ | 7,352,394 | ​ | $ | 390,055 | ​ | $ | 2,569,961 | ​ | $ | 22,621 | ​ | $ | 10,335,031

​

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | For the nine months ended September 30, 2024:
​ |  | ​ | ​ |  | Blood |  | ​ | ​ |  | ​ | ​ |  | ​
​ | ​ | ​ | ​ | ​ | Collection | ​ | EasyPoint® | ​ | Other | ​ | ​ | Total
Geographic Segment | ​ | Syringes | ​ | Products | ​ | Needles | ​ | Products | ​ | ​ | Revenue
U.S. sales | ​ | $ | 14,655,118 | ​ | $ | 991,924 | ​ | $ | 5,615,759 | ​ | $ | 20,545 | ​ | $ | 21,283,346
North and South America sales (excluding U.S.) | ​ |  | 1,325,507 | ​ | ​ | 96 | ​ | ​ | 59,040 | ​ | ​ | 6,240 | ​ |  | 1,390,883
Other international revenue | ​ |  | 961,429 | ​ | ​ | 151,650 | ​ | ​ | 178,276 | ​ | ​ | 10,000 | ​ |  | 1,301,355
Total | ​ | $ | 16,942,054 | ​ | $ | 1,143,670 | ​ | $ | 5,853,075 | ​ | $ | 36,785 | ​ | $ | 23,975,584

​

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | For the nine months ended September 30, 2023:
​ |  | ​ | ​ |  | Blood |  | ​ | ​ |  | ​ | ​ |  | Total
​ | ​ | ​ | ​ | ​ | Collection | ​ | EasyPoint® | ​ | Other | ​ | Product
Geographic Segment | ​ | Syringes | ​ | Products | ​ | Needles | ​ | Products | ​ | Sales
U.S. sales | ​ | $ | 17,022,384 | ​ | $ | 1,123,808 | ​ | $ | 3,944,284 | ​ | $ | 26,385 | ​ | $ | 22,116,861
North and South America sales (excluding U.S.) | ​ |  | 5,596,992 | ​ |  | — | ​ |  | — | ​ |  | 226,290 | ​ |  | 5,823,282
Other international sales | ​ |  | 959,548 | ​ |  | 224,868 | ​ |  | 178,004 | ​ |  | 4,850 | ​ |  | 1,367,270
Total | ​ | $ | 23,578,924 | ​ | $ | 1,348,676 | ​ | $ | 4,122,288 | ​ | $ | 257,525 | ​ | $ | 29,307,413

​

Income taxes

The Company evaluates tax positions taken or expected to be taken in a tax return for recognition in the financial statements based on whether it is “more-likely-than-not” that a tax position will be sustained based upon the technical merits of the position. Measurement of the tax position is based upon the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement.

The Company provides for deferred income taxes through utilizing an asset and liability approach for financial accounting and reporting based on the tax effects of differences between the financial statement and tax bases of assets and liabilities, based on enacted rates expected to be in effect when such differences reverse in future periods. Deferred tax assets are periodically reviewed for realizability. As of September 30, 2024, Management has concluded that a $9.9 million valuation allowance is needed on the net deferred tax asset. As of December 31, 2023, the valuation allowance for state net operating losses was $283 thousand.

Earnings per share

The Company computes basic earnings per share (“EPS”) by dividing net earnings for the period (adjusted for any cumulative dividends for the period) by the weighted average number of common shares outstanding during the period. Diluted EPS includes the determinants of basic EPS and, in addition, reflects the dilutive effect, if any, of the

10

Table of Contents

common stock deliverable pursuant to stock options and/or common stock issuable upon the conversion of convertible preferred stock.

The calculation of diluted EPS under the treasury stock method included the following shares in the three and nine month periods ending September 30, 2024 and 2023:

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | Three Months Ended | ​ | Nine Months Ended | ​ | Nine Months Ended
​ |  | September 30, 2024 |  | September 30, 2023 |  | September 30, 2024 |  | September 30, 2023
Common stock underlying issued and outstanding stock options | ​ | - |  | 6,408 | ​ | 2,706 |  | 17,904
​ | ​ | - |  | 6,408 | ​ | 2,706 |  | 17,904

​

The potential dilution, if any, is shown on the following schedule:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | Three Months Ended | ​ | Nine Months Ended | ​ | Nine Months Ended | ​
​ |  | September 30, 2024 |  | September 30, 2023 |  | September 30, 2024 |  | September 30, 2023 | ​
Net loss | ​ | $ | (1,921,989) | ​ | $ | (4,060,496) | ​ | $ | (15,657,246) | ​ | $ | (6,938,090) | ​
Preferred stock dividend requirements | ​ |  | (57,611) | ​ |  | (58,111) | ​ |  | (172,832) | ​ |  | (174,335) | ​
Loss applicable to common shareholders | ​ | $ | (1,979,600) | ​ | $ | (4,118,607) | ​ | $ | (15,830,078) | ​ | $ | (7,112,425) | ​
Average common shares outstanding | ​ |  | 29,937,159 | ​ |  | 29,937,159 | ​ |  | 29,937,159 | ​ |  | 29,937,159 | ​
Average common and common equivalent shares outstanding — diluted | ​ |  | 29,937,159 | ​ |  | 29,937,159 | ​ |  | 29,937,159 | ​ |  | 29,937,159 | ​
Basic loss per share | ​ | $ | (0.07) | ​ | $ | (0.14) | ​ | $ | (0.53) | ​ | $ | (0.24) | ​
Diluted loss per share | ​ | $ | (0.07) | ​ | $ | (0.14) | ​ | $ | (0.53) | ​ | $ | (0.24) | ​

​

Shipping and handling costs

The Company classifies shipping and handling costs as part of Cost of sales in the Condensed Statements of Operations.

Share-based Compensation

The Company’s share-based payments are accounted for using the Black-Scholes fair value method. The Company generally records share-based compensation expense on a straight-line basis over the requisite service period. The Company records forfeitures as they occur.

Self-insured employee benefit costs

The Company self-insures certain health insurance benefits for its employees under certain policy limits. The Company has additional coverage provided by an insurance company for any individual with claims in excess of $100,000 and/or total plan claims in excess of $1.7 million for the plan year.

Research and development costs

Research and development costs are expensed as incurred.

Technology Investment Agreement (TIA)

Effective July 1, 2020, the Company entered into a Technology Investment Agreement (“TIA”) with the United States Government Department of Defense, U.S. Army Contracting Command-Aberdeen Proving Ground, Natick Contracting Division & Edgewood Contracting Division (ACC-APG, NCD & ECD) on behalf of the Biomedical Advanced Research and Development Authority (BARDA), as amended, for $81,029,518 in government funding for

11

Table of Contents

expanding the Company’s domestic production of needles and syringes. At the request of the US government, the TIA was transferred to a successor agreement, identified as Other Transaction Agreement in April 2023. Such agreement contains no additional requirements and, for the purposes of this report, the agreement shall continue to be referred to herein as the “TIA”. Under this agreement, the Company has made significant additions to its facilities which allows the Company to increase domestic production capacity. For further explanation, please refer to Note 7 – Technology Investment Agreement.

As reimbursements were received from the U.S. government for expenditures under the TIA, the Company recorded a deferred liability. In 2021, the deferred liability began to be systematically amortized as a gain over the life of the related property, plant, and equipment and is presented as Other income – TIA on the Statements of Operations. For any reimbursements received for expenditures not capitalized as property, plant, and equipment, Other income – TIA was recognized in the same period as the expense.

Recently Issued Pronouncements

In November 2024, the FASB issued ASU 2024-03, "Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses." This update enhances the requirements for public companies to provide more detailed and structured disclosures of their expenses, aiming to improve transparency in financial reporting. The new guidance is effective for fiscal reporting periods beginning after December 15, 2026, and for interim periods starting after December 15, 2027. Early adoption is permitted for fiscal financial statements that have not yet been issued or made available for issuance. Companies can choose to apply the amendment either prospectively to periods beginning after the effective date or retrospectively to prior periods presented in their financial statements. The Company is evaluating the adoption of the amendments and the potential impact it may have, if any, on its financial statements.

In March 2024, the FASB issued ASU 2024-02, “Codification Improvements — Amendments to Remove References to the Concepts Statements”, which amends the Codification to remove references to various concepts statements. In most instances, the references are extraneous and not required to understand or apply the guidance. In other instances, the references were used in prior Statements to provide guidance in certain topical areas. ASU 2024-02 is effective for public business entities for fiscal periods beginning after December 15, 2024. For all other entities, it is effective for fiscal years, including interim periods within those fiscal years beginning after December 15, 2025. Early adoption is permitted for all entities, for any fiscal year or interim period for which financial statements have not yet been issued or made available for issuance. The Company is evaluating the new guidance to determine the impact it may have, if any, on its financial statements.

In December of 2023, the FASB issued ASU 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” The updated accounting guidance improves transparency of income tax disclosures, including the disaggregation of existing disclosures related to the effective tax rate reconciliation and income taxes paid. ASU No. 2023-09 is effective for public business entities for annual periods beginning after December 15, 2024. Early adoption is permitted. For all other entities, it is effective for annual periods beginning after December 15, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. Prospective application is required, with retrospective application permitted. The Company is evaluating the adoption of the amendments and the potential impact it may have, if any, on its financial statements.

In June 2022, the FASB issued ASU 2022-03, “Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions”, intended to clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. The amendment also clarifies that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. ASU No. 2022-03 is effective for public business entities for fiscal years, including interim periods within those fiscal years, beginning after December 15, 2023. Early adoption is permitted. For all other entities, it is effective for fiscal years, including interim periods within those fiscal years beginning after December 15, 2024. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. The adoption of the amendments is unlikely to have a material effect on the Company’s financial statements or disclosures.

12

Table of Contents

​

​

​

3. INVENTORIES

Inventories consist of the following:

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | September 30, 2024 |  | December 31, 2023
Raw materials | ​ | $ | 4,255,090 | ​ | $ | 4,349,029
Finished goods | ​ | ​ | 17,045,918 | ​ | ​ | 13,232,339
​ | ​ | $ | 21,301,008 | ​ | $ | 17,581,368

​

​

4. FAIR VALUE OF FINANCIAL INSTRUMENTS

ASC 820, “Fair Value Measurements”, defines fair value, establishes a framework for measuring fair value and requires additional disclosures regarding certain fair value measurements. ASC 820 establishes a three-tier hierarchy for measuring fair value, as follows:

| ● | Level 1 – quoted market prices in active markets for identical assets and liabilities

​

| ● | Level 2 – inputs other than quoted prices that are directly or indirectly observable

​

| ● | Level 3 – unobservable inputs where there is little or no market activity

​

The following tables summarize the values of assets designated as Investments in debt and equity securities:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | September 30, 2024
​ |  | Level 1 |  | Level 2 |  | Level 3 |  | Total
Equity securities | ​ | $ | 19,814,003 | ​ | $ | — | ​ | $ | — | ​ | $ | 19,814,003
Mutual funds | ​ | ​ | 12,289,041 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 12,289,041
Municipal bonds | ​ | ​ | 679,275 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 679,275
​ | ​ | $ | 32,782,319 | ​ | $ | — | ​ | $ | — | ​ | $ | 32,782,319

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | December 31, 2023
​ |  | Level 1 |  | Level 2 |  | Level 3 |  | Total
Equity securities | ​ | $ | 18,282,556 | ​ | $ | — | ​ | $ | — | ​ | $ | 18,282,556
Mutual funds | ​ | ​ | 15,656,757 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 15,656,757
Municipal bonds | ​ |  | 681,900 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 681,900
​ | ​ | $ | 34,621,213 | ​ | $ | — | ​ | $ | — | ​ | $ | 34,621,213

​

The investment assets are held as trading securities and are carried at fair value as of the date of the Condensed Balance Sheets. The Company intends to hold these assets for possible future operating requirements. The following table summarizes gross unrealized gains and losses from Investments in debt and equity securities:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | September 30, 2024
​ | ​ | ​ | ​ | ​ | Cumulative Unrealized | ​ | Aggregate
​ |  | Cost |  | Gains |  | Losses |  | Fair Value
Equity securities | ​ | $ | 24,230,746 | ​ | ​ | — | ​ | ​ | (4,416,743) | ​ | ​ | 19,814,003
Mutual funds | ​ | ​ | 12,177,576 | ​ | ​ | 111,465 | ​ | ​ | — | ​ | ​ | 12,289,041
Municipal bonds | ​ | ​ | 636,187 | ​ | ​ | 43,088 | ​ | ​ | — | ​ | ​ | 679,275
​ | ​ | $ | 37,044,509 | ​ | $ | 154,553 | ​ | $ | (4,416,743) | ​ | $ | 32,782,319

​

13

Table of Contents

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | December 31, 2023
​ | ​ | ​ | ​ | ​ | Cumulative Unrealized | ​ | Aggregate
​ |  | Cost |  | Gains |  | Losses |  | Fair Value
Equity securities | ​ | $ | 24,074,112 | ​ | $ | — | ​ | $ | (5,791,556) | ​ | $ | 18,282,556
Mutual funds | ​ | ​ | 15,576,527 | ​ | ​ | 80,230 | ​ | ​ | — | ​ | ​ | 15,656,757
Municipal bonds | ​ |  | 635,425 | ​ | ​ | 46,475 | ​ | ​ | — | ​ | ​ | 681,900
​ | ​ | $ | 40,286,064 | ​ | $ | 126,705 | ​ | $ | (5,791,556) | ​ | $ | 34,621,213

​

Unrealized losses on investments in debt and equity securities were $1.4 million and $(11.3) million for the nine months ended September 30, 2024 and 2023, respectively.

​

​

​

5. INCOME TAXES

The Company’s effective tax rate on the net loss before income taxes was 1.6% and 23.3% for the three months ended September 30, 2024 and 2023, respectively. The Company’s effective tax rate on the net income before income taxes was (114.7)% and 22.4% for the nine months ended September 30, 2024 and 2023, respectively.

A reconciliation of the federal statutory corporate tax rate to the Company’s effective tax rate is as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Nine Months Ended | ​ | Nine Months Ended | ​ | ​
​ |  | September 30, 2024 |  | September 30, 2023 |  | ​
U.S. statutory federal tax rate |  | 21.00 | % | 21.00 | % |
State tax, net of federal tax |  | (0.11) | % | 0.13 | % |
Change in valuation allowance |  | (132.06) | % | — | % |
Stock options | ​ | — | % | 0.15 | % | ​
Section 162(m); Limit on Compensation | ​ | (0.13) | % | — | % | ​
Other | ​ | (0.13) | % | — | % | ​
Return-to-provision and other |  | (3.27) | % | 1.14 | % |
Effective tax rate |  | (114.70) | % | 22.42 | % |

​

The Company uses the recognition and measurement provisions of the FASB ASC Topic 740, Income Taxes (“Topic 740”), to account for income taxes. The provisions of Topic 740 require a company to record a valuation allowance when the “more likely than not” criterion for realizing net deferred tax assets cannot be met. Furthermore, the weight given to the potential effect of such evidence should be commensurate with the extent to which it can be objectively verified. The Company reviewed the operating results, as well as all of the positive and negative evidence related to realization of such deferred tax assets, to evaluate the need for a valuation allowance. As a result of this review, as of September 30, 2024, the Company concluded that a $9.9 million valuation is needed on the net deferred tax asset. As of December 31, 2023, the valuation allowance for state net operating losses was $283 thousand.

The effective tax rate for the nine months ended September 30, 2024 was different from the federal statutory rate due primarily to the increase of the valuation allowance on the Company’s Deferred tax asset.

​

​

6. OTHER ACCRUED LIABILITIES

Other accrued liabilities consist of the following:

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | September 30, 2024 |  | December 31, 2023
Prepayments from customers | ​ | $ | 379,873 | ​ | $ | 201,492
Accrued property taxes | ​ | ​ | 498,268 | ​ | ​ | —
Accrued professional fees | ​ | ​ | 328,181 | ​ | ​ | 320,899
Current portion – preferred stock repurchase | ​ |  | 6,000 | ​ |  | 6,000
Other accrued expenses | ​ |  | 112,758 | ​ |  | 102,180
Total | ​ | $ | 1,325,080 | ​ | $ | 630,571

​

14

Table of Contents

​

7. TECHNOLOGY INVESTMENT AGREEMENT

Effective July 1, 2020, the Company entered into the Technology Investment Agreement (TIA) with the U.S. government to expand the Company’s manufacturing capacity for hypodermic safety needles in response to the worldwide COVID-19 global pandemic. The award is an expenditure-type TIA, whereby the U.S. government has made payments to the Company for the Company’s expenditures for equipment and supplies related to the expansion. The Company’s contributions under the terms of the TIA include providing facilities, technical expertise, labor and maintenance for the TIA-funded equipment for a ten-year term. In May of 2021, the Company and the U.S. government amended the TIA agreement to include two additional assembly lines and additional controlled environment space.

The Company has received all equipment, has completed all property construction required by the TIA, and all reimbursement requests have been submitted. No further amounts for expansion under the TIA are expected to be submitted or collected.

At the request of the US government, the TIA was transferred to a successor agreement, identified as Other Transaction Agreement in April 2023. Such agreement contains no additional requirements, and, for the purposes of this report, the agreement shall continue to be referred to herein as the “TIA”. The successor agreement governs ongoing terms established by the TIA until June 30, 2030, which includes maintenance of equipment, availability of capacity, and US government preference in the event of a public health emergency.

Under the TIA, reimbursable amounts are reflected as Other long-term liabilities on the Balance Sheets until the time the deferred income can be systematically amortized over a period matching the useful life of the purchased assets. Other long-term liabilities from the TIA were $65,344,155 and $71,517,656 at September 30, 2024 and 2023, respectively.

​

8. COMMITMENTS AND CONTINGENCIES

On November 7, 2019, the Company filed a lawsuit in the 44th District Court of Dallas County, Texas (No. DC-19-17946) against Locke Lord, LLP and Roy Hardin in connection with their legal representation of the Company in its previous litigation against Becton, Dickinson and Company ("BD"). The Company alleged that the defendants breached their fiduciary duties, committed malpractice, and were negligent in their representation of the Company. The Company seeks actual and exemplary damages, disgorgement, costs, and interest. On September 2, 2022, the Company filed a Second Amended Petition alleging legal malpractice and negligence. On February 20, 2024, the Defendants filed another Motion for Summary Judgment on the Company’s remaining claim of legal malpractice. A hearing on that Motion for Summary Judgment was held on April 18, 2024 and an order denying Defendants’ Motion was signed May 10, 2024. A new trial date has been set for June 2, 2025.

​

On September 26, 2024, the Company filed a lawsuit in the United States Court of International Trade against the United States of America, the Office of the United States Trade Representative, Trade Representative Katherine Tai, U.S. Customs & Border Protection, and U.S. Customs & Border Protection Acting Commissioner Troy Miller. Relief sought includes preliminary injunctions on recently enacted tariffs and, ultimately, a decision that the tariffs be set aside, as well as certain costs, fees, and other relief. Defendants filed a motion to dismiss on October 11, 2024 which was later restated on October 15, 2024. An evidentiary hearing was held on October 17, 2024. Post-hearing briefs were filed by the Company and the defendants on October 22, 2024. On October 28, 2024, the Court entered an opinion denying the Company’s motion for a temporary restraining order and preliminary injunction against the collection of tariffs, but ordered that the Company’s motion for preliminary injunction enjoining liquidation of entries during the pendency of the litigation was granted.

​

9. BUSINESS SEGMENT

The Company does not operate in separate reportable segments. Shipments to international customers generally require a prepayment either by wire transfer or an irrevocable confirmed letter of credit. The Company does extend

15

Table of Contents

credit to international customers on some occasions depending upon certain criteria, including, but not limited to, the credit worthiness of the customer, the stability of the country, banking restrictions, and the size of the order. All transactions are in U.S. currency.

Revenues by geography are as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | Three Months Ended | ​ | Nine Months Ended | ​ | Nine Months Ended | ​
​ |  | September 30, 2024 |  | September 30, 2023 |  | September 30, 2024 |  | September 30, 2023 | ​
U.S. sales | ​ | $ | 9,628,608 | ​ | $ | 9,392,737 | ​ | $ | 21,283,346 | ​ | $ | 22,116,861 | ​
North and South America sales (excluding U.S.) | ​ |  | 569,970 | ​ |  | 839,730 | ​ |  | 1,390,883 | ​ |  | 5,823,282 | ​
Other international sales | ​ |  | 148,279 | ​ |  | 102,564 | ​ |  | 1,301,355 | ​ |  | 1,367,270 | ​
Total sales | ​ | $ | 10,346,857 | ​ | $ | 10,335,031 | ​ | $ | 23,975,584 | ​ | $ | 29,307,413 | ​

​

Long-lived assets by geography are as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | September 30, 2024 |  | December 31, 2023 | ​
Long-lived assets | ​ | ​ | ​ | ​ | ​ | ​ | ​
U.S. | ​ | $ | 84,883,113 | ​ | $ | 89,237,030 | ​
International | ​ | ​ | 4,053,797 | ​ | ​ | 4,241,491 | ​
Total | ​ | $ | 88,936,910 | ​ | $ | 93,478,521 | ​

​

​

​

10. DIVIDENDS

A payment of $39,050 was paid within one month of each quarter’s end in 2023 and in January, April, and July of 2024 to Series II preferred shareholders. Series III preferred shareholders were paid a cash dividend of $19,061 within one month of each quarter’s end in 2023. A payment of $18,561 was made to Series III shareholders in January, April, and July of 2024.

​

In June 2021, the Board of Directors approved payments to its Series II, Series III, and former Series IV and Series V Class B Preferred Shareholders in the cumulative amount of $5,056,945 representing all current dividends, dividends in arrears, as well as dividends still owed to shareholders who converted their preferred stock in the past. The dividends were paid on July 22, 2021 to all shareholders who had been contacted and confirmed as the rightful owner entitled to payment. The Company has not yet established contact with all former shareholders, most of whom converted their shares prior to 2001. The Company is continuing its efforts to establish contact with approximately 90 former shareholders who are entitled to approximately $1.4 million. This, along with the current declared dividends, are reflected in Dividends payable on the Condensed Balance Sheets.

​

​

​

11. PRIVATE EXCHANGES AND REDEMPTION

In 2020, the Company entered into several agreements with shareholders to purchase its outstanding Class B Convertible Preferred Stock. The consideration for these purchases consisted of both cash and Common Stock. In addition, in each such transaction, the preferred shareholder counterparty waived all rights to unpaid dividends in arrears. The aggregate cash consideration equaled $3,786,000, of which $482,670 was paid in 2020. The balance was paid in equal installments of $1,101,110 over a three-year period which began in February 2021 and the last payment was made in February 2023.

​

Effective November 2023, the Company entered into a privately negotiated transaction with a preferred shareholder to redeem 2,000 shares of Series III Class B Stock for a purchase price equal to approximately $6 thousand.

​

12. TREASURY STOCK

Treasury share purchases are accounted for under the cost method and are included as a component of treasury stock in the Company’s balance sheets.

16

Table of Contents

​

Of the 100 million authorized shares of Common Stock, 34,024,304 shares were issued and 29,937,159 shares outstanding as of both December 31, 2023 and September 30, 2024.

​

ANY SUBSEQUENT EVENTS?

​

​

​

​

​

​

​

​

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

FORWARD-LOOKING STATEMENT WARNING

Certain statements included by reference in this filing containing the words “could,” “may,” “believes,” “anticipates,” “intends,” “expects,” and similar such words constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Any forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, among others: tariffs, material changes in demand; our ability to maintain liquidity; our maintenance of patent protection; our ability to maintain favorable third party manufacturing and supplier arrangements and relationships; foreign trade risk; our ability to access the market; production costs; the impact of larger market players in providing devices to the safety market; and any other factors referenced in Item 1A. Risk Factors in Part II. Given these uncertainties, undue reliance should not be placed on forward-looking statements.

MATERIAL CHANGES IN FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Overview

We have been manufacturing and marketing our products since 1997. Syringes comprised 70.7% of our sales in the first nine months of 2024. EasyPoint® products accounted for 24.4% and other products, including our IV safety catheter and blood collection products, were 4.8% of our sales in the first nine months of 2024.

Our products have been and continue to be distributed nationally and internationally through numerous distributors. Some of our popular syringe products provide low dead-space. Low dead-space syringes reduce residual medication remaining in the syringe after the dose has been administered. In some instances, the low dead-space allows for additional doses of medication to be obtained from the vials.

On September 13, 2024, the Office of the U.S. Trade Representative (“USTR”) revealed final adjustments to increase tariffs on certain goods imported from China under Section 301 of the Trade Act of 1974. Among those products included were syringes and needles, at a rate of 100%. As previously noted, for the first nine months of 2024, 90% of the products the Company obtained were purchased from our manufacturers in China, most of which are impacted by the tariffs. The adjusted tariffs were effective on September 27, 2024. Tariffs are expected to have a material impact to our results of operations and financial position. To date, the Company has incurred $568 thousand in tariff expenses and due to existing orders from our Chinese manufacturers, we expect to incur a total of approximately $1.5 million in tariff expenses through February 2025. We are working to lessen the financial impact of the tariffs, including shifting a larger portion of manufacturing of 1mL, 3mL, and EasyPoint® needles to our domestic manufacturing facility, but while these actions would decrease tariff expenses, they would lead to an increase in compensation expense as we must hire additional manufacturing personnel. Certain products must be purchased from third party suppliers as we do not currently have the machinery to manufacture our entire product line in our U.S. facility. When equipment was added to our U.S. facility pursuant to the TIA, it was strictly for product lines typically used in the administration of vaccines, as required by the TIA. We have sued the USTR and other defendants involved in the issuance of the recent tariff adjustment as described in Note 8 to the financial statements seeking an injunction and, ultimately, a decision that the tariffs be set aside, as well as certain costs, fees, and other relief. Some of our requests for injunctions were denied as described in Note 8 to the financial statements and therefore we are currently subject to the tariffs during the pendency of the case. Tariffs at the

17

Table of Contents

100% level without sufficient time to increase our domestic production would considerably increase our costs and may cause irreparable harm.

In 2020 and 2021, we were awarded significant orders and contracts by the U.S. government for safety syringes for COVID-19 vaccination efforts. From 2020 through the first quarter of 2022, the U.S. government was a significant customer. We cannot predict whether any future U.S. government orders may occur.

In 2020, we entered into a Technology Investment Agreement (“TIA”) with the U.S. government which provided significant government funding for expanding our domestic production of needles and syringes to meet ongoing and future U.S. COVID-19 medical countermeasures demands. Recent additions of manufacturing equipment and facilities have increased our production capacity and our overhead costs. There are currently no plans to further expand our production or administrative facilities, nor do we have material commitments for additional manufacturing equipment purchases. At the request of the US government, the TIA was transferred to a successor agreement, identified as Other Transaction Agreement in April 2023. Such agreement contains no additional requirements, and, for the purposes of this report, the agreement shall continue to be referred to herein as the “TIA”. The successor agreement governs ongoing terms established by the TIA until June 30, 2030, which includes maintenance of equipment, availability of capacity, and US government preference in the event of a public health emergency.

The U.S. government orders as well as the TIA are material events particular to the COVID-19 pandemic and are not indicative of future operations.

Over the past several years, we have experienced certain cost increases in raw materials, but those costs primarily affect our domestic manufacturing because the finished goods we purchased from China (being 90% of our products) have been subject to a long-term fixed price contract. Other factors that could affect our unit costs include tariffs, supplier cost increases, and changing production volumes. Increases in costs may not be recoverable through price increases of our products.

​

We believe domestic customers have retained products provided for vaccination purposes in inventory, leading to a decrease in our 2023-2024 domestic sales. Customers have reported that demand was diminished due to their remaining syringe inventory. It is difficult to estimate how much of the remaining inventory might still remain in the market.

As detailed in Note 4 to the financial statements, we held $32.8 million in debt and equity securities as of September 30, 2024, which represented 20.8% of our total assets.

Historically, unit sales have increased during the flu season. From approximately 2020-2022, the effect of flu season sales was less impactful due to the dramatic increase in sales attributable to COVID-19 vaccinations. Seasonal trends for syringe sales may now be following pre-pandemic patterns. Additionally, we believe there may be more demand for EasyPoint® products during flu season.

In the third quarter of 2024, our Chinese manufacturers produced approximately 87.3% of our products.

A material portion of our net losses for the nine months ended September 30, 2024 is comprised of the approximately $8.4 million change in valuation allowance which occurred in the second quarter of 2024 on the deferred tax asset which is included as a provision for income taxes on the Condensed Statements of Operations. The devaluation of the deferred tax asset was related to our determination that, based on current information, it was more likely than not that we wouldn’t be in a position to use loss carryforwards against future taxable net income based on a variety of factors and accounting guidelines. The announced implementation of tariffs on imported syringes from China was one of the factors considered in this determination.

In 1995, we entered into a license agreement with Thomas J. Shaw for the exclusive right to manufacture, market, and distribute products utilizing his patented automated retraction technology and other patented technology. This technology is the subject of various patents and patent applications owned by Mr. Shaw. The license agreement generally

18

Table of Contents

provides for quarterly payments of a 5% royalty fee on gross sales of products subject to the license and he receives fifty percent (50%) of the royalties paid to us by certain sublicensees of the technology subject to the license.

Included in net sales for the third quarter of 2024 is $38 thousand in licensing fees recorded under a sublicensing agreement with one of our Chinese manufacturers. Under the terms of our licensing agreement with Mr. Shaw, he is entitled to receive 50% of this amount, which is recorded as royalty expense to shareholder in total cost of sales for the year.

​

RESULTS OF OPERATIONS

​

The following discussion may contain trend information and other forward-looking statements that involve a number of risks and uncertainties. Our actual future results could differ materially from our historical results of operations and those discussed in any forward-looking statements. All period references are to periods ended September 30, 2024 or 2023, as applicable. Dollar amounts have been rounded for ease of reading.

​

Comparison of Three Months Ended September 30, 2024 and September 30, 2023

Domestic sales accounted for 93.1% and 90.9% of the revenues for the three months ended September 30, 2024 and 2023, respectively. Domestic revenues were essentially flat while domestic unit sales increased 29.6%. Domestic unit sales were 92.4% of total unit sales for the three months ended September 30, 2024. The increase in unit sales not contributing to domestic revenues was primarily driven by a decrease in the average selling price, largely due to higher sales of our EasyPoint® needles, which typically have a lower average selling price. International revenues decreased approximately 23.8%. The decrease in international revenues is primarily due to the timing of international shipments. Overall unit sales increased 22%. There is uncertainty as to the timing of future international orders.

Cost of manufactured product increased 81.6% principally due to a rise in the volume of units sold, higher period costs associated with increased sales, and additional period costs related to increased domestic production activities. Royalty expense increased 11.4% primarily due to the increase in gross sales and royalties received from sublicenses.

The gross profit margin decreased from 41.8% to (0.1%) for the three months ended September 30, 2024. This decline was primarily driven by a decrease in the average selling price, a drop in international sales, and rising production costs. Despite the increase in unit sales, these factors contributed to the overall reduction in gross profit.

Operating expenses were essentially flat, with a slight decrease of 2.6% compared to the three months ended September 30, 2023.

The loss from operations was $5.1 million compared to a loss of $936 thousand for the same period last year. The increased loss was due to lower gross profit for the current period.

​

The unrealized gain on debt and equity securities was $1.5 million due to the increased market values of those securities.

The benefit for income taxes was $31 thousand for the third quarter of 2024 as compared to a benefit for income taxes of $1.2 million in the third quarter of 2023. This change is primarily due to the increase in valuation allowance on our deferred tax asset in the second quarter of 2024.

Tariffs are expected to materially increase our costs in future periods.

Comparison of Nine Months Ended September 30, 2024 and September 30, 2023

Domestic sales accounted for 88.8% and 75.5% of the revenues for the nine months ended September 30, 2024 and 2023, respectively. Domestic unit sales increased 10.7% while domestic revenues decreased 3.8% primarily due to the mix of products sold. This decline in revenues was largely driven by a decrease in the average selling price, mainly resulting from increased sales of our EasyPoint® needles, which typically have a lower average selling price. Domestic

19

Table of Contents

unit sales were 87.6% of total unit sales for the nine months ended September 30, 2024. International revenues decreased approximately 62.6% predominately due to fewer international vaccination-related sales. Overall unit sales decreased 16.1%. There is uncertainty as to the timing of future international orders.

Cost of manufactured product remained largely consistent, with a slight increase of 4.4%. This change was primarily driven by a decrease in the volume of units sold, partially offset by higher period costs associated with increased domestic production activities.

Operating expenses decreased 5.7% from the prior year. This is substantially due to a reduction of property tax expense as a result of newly enacted property tax exemption legislation relating to medical device property. The decrease was partially offset by an increase in sales and marketing expenses.

The loss from operations was $13.9 million compared to a loss of $8.7 million for the same period last year. The increased loss was due to lower gross profit for the current period.

The unrealized gain on debt and equity securities was $1.4 million due to the increased market values of those securities.

The provision for income taxes was $8.4 million for the first nine months of 2024 as compared to a benefit for income taxes of $1.9 million in the first nine months of 2023. The year-to-date income tax provision is primarily related to fully reserving our deferred tax asset in the second quarter of 2024.

Tariffs are expected to materially increase our costs in future periods.

Discussion of Balance Sheet and Cash Flow Items

​

Cash and investments comprise 23.3% of total assets. Cash flow used by operations was $10.5 million for the nine months ended September 30, 2024 due to a number of factors. We recognized approximately $4.4 million in other income from the TIA during the first nine months of 2024, offset by an increase of $8.4 million in valuation allowance related to deferred tax assets which is material to the adjustments to total cash flow from operations. Changes in working capital also impacted cash flows from operating activities. Accounts receivable decreased by $1.6 million, inventories increased by $3.7 million, and accounts payable decreased by $1.5 million.

Cash flow from investing activities was $2.1 million for the nine months ended September 30, 2024 due to the purchase of assets and net sale of securities.

Cash flow used by financing activities was $398 thousand for the nine months ended September 30, 2024 due to repayments of long-term debt and payment of preferred stock dividends.

LIQUIDITY AND CAPITAL RESOURCES

​

We have historically funded operations primarily from the proceeds from revenues, private placements, litigation settlements, and loans. We may fund operations going forward from revenues, cash reserves, and investments in trading securities should the need to access those funds arise.

​

The imposition of 100% tariffs on our imported syringe and needle products will have a material effect on our operating results and liquidity. There have been no such tariffs incurred during the periods represented in this report but such tariffs were enacted effective September 27, 2024. To date, the Company has incurred $568 thousand in tariff expenses, and due to existing orders from our Chinese manufacturers, we expect to incur a total of approximately $1.5 million in tariff expenses through February 2025. Additional capital improvements and increases to our manufacturing workforce will also increase expenses in the near-term as a result of the tariffs and our expected increase in domestic manufacturing.

​

20

Table of Contents

Margins

The mix of domestic and international sales, along with product mix, affects the average sales price of our products. Generally, the higher the ratio of domestic sales to international sales, the higher the average sales price will be. Additionally, product mix plays a role, with syringe sales typically having higher average selling prices and gross profit margins than our other product lines. Some international sales of our products are shipped directly from China to the customer. The number of units produced by us versus manufactured in China can have a significant effect on the carrying costs of Inventory as well as Cost of sales. Generally, an overall increase in units sold can positively affect our margins. The cost of raw materials used in manufacturing, transportation costs, and the impact of tariffs can also significantly affect our margins. We will continue to evaluate the appropriate mix of products manufactured domestically and those manufactured in China to achieve economic benefits as well as to maintain our domestic manufacturing capability.

Cash Requirements

We believe we will have adequate means to meet our short-term needs to fund operations for at least 12 months from the date of issuance of the financial statements. Besides cash reserves and expected income from operations, we also have access to our investments which may be liquidated in the event that we need to access the funds for operations. Expected short-term uses of cash include payroll and benefits, royalty expense, inventory purchases, tariffs, contractual obligations, payment of income taxes, quarterly preferred stock dividends, and other operational priorities. Our liabilities are our bank debt as set forth as Long-term debt on our Condensed Balance Sheets and other liabilities detailed herein in Note 6 to the financial statements. We believe we will have adequate means to meet our currently foreseeable long-term liquidity needs although the new tariffs and our costs related to an increase in domestic manufacturing will increase our expenses materially. For the next 1-3 years, we believe our liquidity will decline materially but expect that we may be able to satisfy our long-term cash requirements using a combination of cash and liquidation of our equity investments. If cash needs cannot be met using existing cash and investments, management would reduce operational costs.

Capital Resources

We expect to spend approximately $1 million over the next few months using existing cash reserves to convert a portion of our domestic equipment to align to our plan to produce more units at our U.S. facility. While additional equipment expenditures may be necessary in the future, this near-term equipment conversion is expected to be completed by the second quarter of 2025.

CRITICAL ACCOUNTING ESTIMATES

We are responsible for developing estimates for amounts reported as assets and liabilities, and revenues and expenses in conformity with U.S. generally accepted accounting principles (“GAAP”). Those estimates require that we develop assumptions of future events based on past experience and expectations of economic factors. Among the more critical estimates management makes is the estimate for customer rebates. The amount reported as a contractual allowance for rebates involves examination of past historical trends related to our sales to distributors and the related credits issued once our distributors have satisfied their contractual obligations. The estimate includes consideration of historical redemption rates, discount rates, a combination of estimated distributor inventories based on tracking information provided by the distributors or if known, inventory turnover rates. The establishment of a liability for future claims of rebates against sales in the current period requires that we have an understanding of the relevant sales with respect to product categories, sales distribution channels, and the likelihood of contractual obligations being satisfied. We examine the results of estimates against actual results historically and use the determination to further develop our basis for assumptions in future periods, as well as the accuracy of past estimates. Based on distributors purchasing and claiming rebates practices, we do not expect significant changes to the current inputs and assumption used in the estimate calculations. While we believe that we have sufficient historical data, and a firm basis for establishing reserves for contractual obligations, there is an inherent risk that our estimates and the underlying assumptions may not reflect actual future results. In the event that these estimates and/or assumptions are incorrect, adjustments to our reserves may have a material impact on future results. As of September 30, 2024, we estimate that the total potential future credits to be issued as a result of prior purchases which have not yet been claimed is $1.8 million.

​

21

Table of Contents

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Not applicable.

​

Item 4. Controls and Procedures.

Disclosure Controls and Procedures

Pursuant to Rule 13a-15(b) of the Securities Exchange Act of 1934, Management, with the participation of our President, Chairman, and Chief Executive Officer, Thomas J. Shaw (the “CEO”), and our Vice President and Chief Financial Officer, John W. Fort III (the “CFO”), acting in their capacities as our principal executive and principal financial officers, evaluated the effectiveness of our disclosure controls and procedures, as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934. The term disclosure controls and procedures means controls and other procedures that are designed to ensure that information required to be disclosed by us in our periodic reports is: i) recorded, processed, summarized, and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms; and ii) accumulated and communicated to our Management, including our principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Based upon this evaluation, the CEO and CFO concluded that, as of September 30, 2024, our disclosure controls and procedures were effective.

Changes in Internal Control Over Financial Reporting

There have been no changes during the third quarter of 2024 or subsequent to September 30, 2024 in our internal control over financial reporting that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

​

PART II—OTHER INFORMATION

Item 1. Legal Proceedings.

Please refer to Note 8 to the financial statements for a complete description of all legal proceedings.

Item 1A. Risk Factors.

​

In addition to the risk factors disclosed in our most recent annual report which is available on EDGAR, the following additional risk factor has been identified.

​

Recently enacted tariffs on our products are expected to have a material negative impact to our results of operations and financial position. We are working to lessen the financial impact of the tariffs, including shifting a larger portion of manufacturing of 1mL, 3mL, and EasyPoint® needles to our domestic manufacturing facility, but these actions will be expensive and the timeline remains uncertain. Likewise, our lawsuit to exempt our payment of tariffs may not succeed. Consequently, we expect a material increase in costs which is expected to materially impact our operations and may impact long-term viability.

Item 5. Other Information.

​

No director or officer terminated a trading arrangement in the third quarter of 2024 of the type described by Item 408 of Regulation S-K. As previously reported, on August 22, 2023, Thomas J. Shaw, President, Chairman, and Chief Executive Officer, adopted a written plan for the purchase of Retractable Technologies, Inc. common stock intended to satisfy the affirmative defense conditions of Rule 10b5–1(c). In accordance with the plan, trading began on November 20, 2023 and may continue through November 19, 2024 if not earlier terminated. During this period, the plan instructs a broker-dealer to purchase common stock for an aggregate purchase price of up to $800,000 within certain price parameters. Mr. Shaw’s purchases pursuant to this plan are reported on forms filed with the SEC pursuant to Section 16(a) of the Securities Exchange Act of 1934.

​

22

Table of Contents

On August 22, 2024, Thomas J. Shaw, President, Chairman, and Chief Executive Officer, adopted a written plan for the purchase of Retractable Technologies, Inc. common stock intended to satisfy the affirmative defense conditions of Rule 10b5–1(c). The plan provides that trading may begin November 20, 2024 and may continue through November 19, 2025 if not earlier terminated. During this period, the plan instructs a broker-dealer to purchase common stock for an aggregate purchase price of up to $800,000 within certain price parameters.

​

Item 6. Exhibits.

​ | ​ | ​
Exhibit No. |  | Description of Document
​ | ​ | ​
31.1 | ​ | Certification of Principal Executive Officer
​ | ​ | ​
31.2 | ​ | Certification of Principal Financial Officer
​ | ​ | ​
32 | ​ | Certification Pursuant to 18 U.S.C. Section 1350
​ | ​ | ​
101 | ​ | The following materials from Retractable Technologies, Inc.’s Form 10-Q for the period ended September 30, 2024, formatted in inline XBRL (eXtensible Business Reporting Language): (i) Condensed Balance Sheets as of September 30, 2024 and December 31, 2023, (ii) Condensed Statements of Operations for the three and nine months ended September 30, 2024 and 2023, (iii) Condensed Statements of Cash Flows for the nine months ended September 30, 2024 and 2023, (iv) Condensed Statement of Changes in Stockholders’ Equity for the three and nine months ended September 30, 2024 and 2023; and (v) Notes to Condensed Financial Statements
​ | ​ | ​
104 | ​ | Interactive Data File (formatted Inline XBRL and contained in Exhibit 101)

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

​

DATE: November 14, 2024 | RETRACTABLE TECHNOLOGIES, INC.
​ | (Registrant)
​ | ​ | ​
​ | ​ | ​
​ | By: | /s/ John W. Fort III
​ | ​ | JOHN W. FORT III VICE PRESIDENT, CHIEF FINANCIAL OFFICER, AND CHIEF ACCOUNTING OFFICER

​

​

​

​

​

​

23